Discover how Leqembi (lecanemab), a new FDA-approved treatment for Alzheimer’s disease, works. Learn about its benefits, side effects, cost, availability, and why it offers hope to millions.
Alzheimer’s disease is one of the most heart-wrenching illnesses of our time. It slowly robs people of their memory, ability to think, and ultimately, their independence. For years, scientists and families alike have searched for something—anything—that could slow this relentless disease.
Now, there’s a new beacon of hope: Leqembi (lecanemab).
Approved by the U.S. FDA in 2023 and making waves in the global medical community, Leqembi isn’t just another experimental drug. It’s the first Alzheimer’s medication shown to significantly slow the progression of the disease, especially when taken in the early stages.
But what exactly is Leqembi? How does it work? Who can take it, and what should patients and caregivers know?
Let’s take a deep dive into everything you need to know about this promising new treatment.
What Is Leqembi (Lecanemab)?
Leqembi is the brand name for lecanemab, a monoclonal antibody treatment developed by Eisai Co. Ltd. in partnership with Biogen Inc. It was granted full FDA approval in July 2023 for treating early Alzheimer’s disease, specifically mild cognitive impairment or mild dementia due to Alzheimer’s.
What makes it revolutionary is that unlike older treatments, which only tried to manage symptoms, Leqembi targets one of the root causes of the disease: amyloid beta plaques in the brain.
These plaques are abnormal protein clumps that build up in the brains of people with Alzheimer’s. Over time, they damage brain cells and lead to the memory loss and confusion we associate with the disease.
How Does Leqembi Work?
Leqembi is an anti-amyloid beta protofibril antibody. That’s a scientific way of saying it helps the body’s immune system target and remove harmful amyloid beta proteins before they form sticky plaques.
Here’s how it works in simpler terms:
- Targets Toxic Clumps: Leqembi recognizes and binds to toxic forms of amyloid beta.
- Removes the Plaques: Once attached, it signals the immune system to clear them out of the brain.
- Slows Disease Progression: By reducing plaque buildup, it slows the damage to brain cells.
In clinical trials, patients who received Leqembi showed a 27% slower decline in memory and thinking over 18 months compared to those who got a placebo.
Who Can Use Leqembi?
Leqembi is not for everyone with Alzheimer’s. It’s specifically approved for people in the early stages of the disease—those with mild cognitive impairment (MCI) or mild Alzheimer’s dementia and confirmed amyloid presence in the brain.
To be eligible, patients typically need:
- A diagnosis of early Alzheimer’s
- Confirmation of amyloid plaques through PET scans or spinal fluid tests
- Regular access to medical monitoring, as the drug requires frequent infusions and check-ups
It’s not recommended for late-stage Alzheimer’s patients, as the benefit appears limited once major brain damage has occurred.
How Is Leqembi Administered?
Leqembi is given through an intravenous (IV) infusion every two weeks.
Each infusion takes about an hour and must be done at a medical center or hospital. It’s not a pill or injection you can take at home.
Because the drug works with the immune system and enters the brain, regular MRI scans are required to monitor for any brain swelling or bleeding—a rare but serious potential side effect.
What Are the Side Effects of Leqembi?
Like any medication, Leqembi isn’t without risks.
The most common side effects include:
- Infusion-related reactions (chills, fever, rash, nausea)
- Headache
- Falls or dizziness
- Brain swelling or bleeding (ARIA) – Amyloid-Related Imaging Abnormalities
ARIA can be serious but is often asymptomatic. This is why MRI monitoring is mandatory before and during treatment.
Some patients, especially those carrying a genetic variant called APOE4, are at higher risk for these complications.
How Much Does Leqembi Cost?
The list price of Leqembi is around $26,500 per year in the U.S.
But the actual out-of-pocket cost depends on your location and insurance status. In the U.S., Medicare has agreed to cover it under specific conditions, including mandatory participation in a registry to track patient outcomes.
In other countries, pricing and availability may vary. Eisai has indicated they’re working to expand global access, especially in markets like Japan, the EU, and Asia.
Is Leqembi Available in Nepal or India?
As of mid-2025, Leqembi is not yet widely available in Nepal or India, but efforts are underway to gain regulatory approval in multiple countries.
If you’re in South Asia and seeking treatment options, here’s what you can do:
- Contact top neurology centers (like AIIMS in India or major hospitals in Kathmandu) to inquire about trials or compassionate use access
- Watch for local FDA or DCGI announcements about approval timelines
- Consult a neurologist for up-to-date advice and possible alternative treatments
How Effective Is Leqembi?
This is the big question on everyone’s mind.
In the Clarity AD Phase 3 trial, the results were promising but not miraculous:
- Patients taking Leqembi declined 27% more slowly than those on placebo over 18 months.
- The difference was modest but meaningful—patients kept more of their memory and independence for longer.
While it doesn’t stop or reverse the disease, it does offer more “quality time” in the earlier stages—precious months or years of better functioning.
For many families, that’s invaluable.
Real Stories: How Leqembi Is Changing Lives
Since its approval, Leqembi has been prescribed to thousands of patients in the U.S. and Japan. One such story is of Linda, a 68-year-old from New York, who began treatment shortly after her diagnosis.
“Before Leqembi, I was forgetting my grandchildren’s names. Now, I can still read to them at night. I feel like I got some of myself back,” she shared in an Eisai interview.
These stories are heartening. While not everyone sees the same results, Leqembi represents real hope—something that was missing from Alzheimer’s care for decades.
Why Is Leqembi a Breakthrough?
For years, the Alzheimer’s drug pipeline was filled with failures. Treatments focused mostly on managing symptoms like confusion or agitation.
Leqembi is different. It’s part of a new wave of disease-modifying therapies (DMTs) that actually alter the course of the disease.
That’s a huge shift.
With more drugs like donanemab and remternetug in the pipeline, Leqembi may just be the first of many tools to finally tackle Alzheimer’s from the inside out.
Ethical Concerns and Accessibility
Of course, no new treatment comes without challenges.
Cost and Equity:
The high cost and need for regular infusions and monitoring mean that many low- and middle-income countries will face hurdles in adopting Leqembi.
Informed Consent:
Because side effects like brain swelling are real, patients and families must be clearly informed before starting treatment.
Longevity vs. Quality:
The benefit is real but not dramatic. Patients and caregivers should weigh the modest slowing of decline against potential risks and costs.
The Future of Alzheimer’s Care: What Comes Next?
Leqembi is not a cure—but it’s a critical first step toward one.
Its approval marks the beginning of a new era in Alzheimer’s research, where biological causes are targeted early, and patients may finally have a chance to hold onto their memories a little longer.
In the future, experts hope to:
- Combine drugs like Leqembi with lifestyle therapies (diet, exercise, cognitive training)
- Personalize treatment based on genetics and biomarkers
- Use early detection tools to identify Alzheimer’s before symptoms even appear
Final Thoughts: Should You Consider Leqembi?
If you or a loved one is facing an early Alzheimer’s diagnosis, Leqembi may be worth considering.
However, it’s not a decision to take lightly. Consult a qualified neurologist. Get the proper tests. Understand the risks and benefits.
And most of all—don’t lose hope.
While Alzheimer’s remains a deeply challenging disease, Leqembi proves that science is fighting back, and progress—real progress—is